Segall Bryant & Hamill LLC Has $25.11 Million Holdings in STERIS plc (NYSE:STE)

Segall Bryant & Hamill LLC grew its position in STERIS plc (NYSE:STE - Free Report) by 5.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 103,547 shares of the medical equipment provider's stock after acquiring an additional 5,506 shares during the quarter. Segall Bryant & Hamill LLC owned 0.10% of STERIS worth $25,114,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the company. West Coast Financial LLC boosted its stake in STERIS by 2.8% during the third quarter. West Coast Financial LLC now owns 1,640 shares of the medical equipment provider's stock worth $398,000 after buying an additional 45 shares in the last quarter. Taylor Frigon Capital Management LLC increased its stake in STERIS by 0.8% in the second quarter. Taylor Frigon Capital Management LLC now owns 6,175 shares of the medical equipment provider's stock valued at $1,356,000 after acquiring an additional 46 shares during the period. Mather Group LLC. increased its stake in STERIS by 7.6% in the second quarter. Mather Group LLC. now owns 763 shares of the medical equipment provider's stock valued at $172,000 after acquiring an additional 54 shares during the period. EverSource Wealth Advisors LLC raised its position in STERIS by 16.5% in the first quarter. EverSource Wealth Advisors LLC now owns 402 shares of the medical equipment provider's stock worth $82,000 after purchasing an additional 57 shares in the last quarter. Finally, Waterloo Capital L.P. lifted its stake in STERIS by 3.2% during the second quarter. Waterloo Capital L.P. now owns 1,916 shares of the medical equipment provider's stock worth $421,000 after purchasing an additional 59 shares during the period. Institutional investors and hedge funds own 94.69% of the company's stock.

STERIS Price Performance

STE traded down $1.20 during trading on Wednesday, hitting $210.80. The company's stock had a trading volume of 362,235 shares, compared to its average volume of 492,664. The firm's 50 day moving average price is $229.10 and its two-hundred day moving average price is $228.69. The company has a quick ratio of 1.55, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. STERIS plc has a 12 month low of $195.47 and a 12 month high of $248.24. The stock has a market capitalization of $20.81 billion, a price-to-earnings ratio of 48.40 and a beta of 0.85.

STERIS (NYSE:STE - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.12 by $0.02. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The firm had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.33 billion. During the same quarter in the previous year, the company posted $2.03 EPS. The business's revenue for the quarter was up 7.3% compared to the same quarter last year. Sell-side analysts forecast that STERIS plc will post 9.15 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th will be paid a $0.57 dividend. The ex-dividend date is Tuesday, November 19th. This represents a $2.28 annualized dividend and a dividend yield of 1.08%. STERIS's dividend payout ratio (DPR) is currently 52.05%.

Insider Activity

In other news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the sale, the chief financial officer now directly owns 42,930 shares of the company's stock, valued at approximately $10,603,710. This trade represents a 35.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.14% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on STE shares. Stephens reiterated an "overweight" rating and issued a $260.00 price objective on shares of STERIS in a research note on Thursday, November 7th. StockNews.com downgraded STERIS from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, October 29th. Needham & Company LLC restated a "hold" rating on shares of STERIS in a research report on Friday, November 8th. JMP Securities restated a "market outperform" rating and set a $265.00 target price on shares of STERIS in a research report on Monday. Finally, Piper Sandler upgraded STERIS from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $230.00 to $260.00 in a research report on Thursday, October 24th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $253.00.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.